Brief: Gamida Cell Announces Dosing Of First Patient In Company-Sponsored Phase 1/2 Study Of NK Cell Therapy Candidate GDA-201
10/08/2022 12:15
Aug 10 (Reuters) - Gamida Cell Ltd GMDA.O :
* GAMIDA CELL ANNOUNCES DOSING OF FIRST PATIENT IN
COMPANY-SPONSORED PHASE 1/2 STUDY OF NK CELL THERAPY CANDIDATE
GDA-201
Source text for Eikon: ID:nBw2mBg8Na
Further company coverage: GMDA.O
Recent news on Gamida Cell
See all newsBrief: Gamida Cell Appoints Joe Wiley As CEO
Brief: Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding
Israeli ADRs up on hopes of de-escalation in Israel-Iran tensions
Brief: Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive
Brief: Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq